C12orf60: A Promising Drug Target and Biomarker for Chromosome 12 Open Reading Frame 60

Target Name: C12orf60

NCBI ID: G144608

C12orf60

Other Name(s): chromosome 12 open reading frame 60 | Chromosome 12 open reading frame 60 | CL060_HUMAN | MGC47869 | Uncharacterized protein C12orf60

C12orf60: A Promising Drug Target and Biomarker for Chromosome 12 Open Reading Frame 60

Introduction

Chromosome 12 (C12) is one of the chromosomes responsible for generating the majority of the cell's DNA. Open reading frame (ORF) 60, also known as exon 12, is a non-coding RNA molecule located at position 60 on chromosome 12. ORF 60 is involved in the regulation of various cellular processes, including cell adhesion, migration, and invasion. C12orf60 has also been implicated in the development and progression of various diseases, making it an attractive drug target and biomarker.

C12orf60 as a Drug Target

C12orf60 has been identified as a potential drug target due to its unique structure and various cellular functions. One of its conserved domains, the N-terminal alpha-helix, is known to play a critical role in the stability and localization of proteins in the nucleus . This domain also interacts with various DNA-binding proteins, increasing its potential to modulate gene expression and contribute to the regulation of cellular processes.

Additionally, C12orf60 has been shown to interact with the protein kinase kinase A1 (PKA) kinase, which is known to play a role in the regulation of cellular processes such as cell growth, differentiation, and survival. The interaction between C12orf60 and PKA kinase suggests that targeting C12orf60 may result in the inhibition of PKA-mediated cellular processes, leading to potential therapeutic benefits.

C12orf60 as a Biomarker

C12orf60 has also been identified as a potential biomarker for various diseases, including cancer. Its involvement in the regulation of cellular processes makes it a promising candidate for the development of diagnostic tests for cancer. For instance, C12orf60 has been shown to be expressed in various types of cancer, including breast, ovarian, and colorectal cancer. This suggests that its levels may be affected by cancer, providing a potential target for diagnostic tests.

Furthermore, C12orf60 has been shown to be involved in the regulation of cell adhesion and migration, which are critical processes in cancer progression. The inhibition of C12orf60 function may lead to the disruption of these processes, leading to the inhibition of cancer cell growth and migration. . This suggests that targeting C12orf60 may be an effective way to treat cancer by inhibiting its role in these processes.

Conclusion

C12orf60 is a promising drug target and biomarker for various diseases. Its unique structure and various cellular functions make it an attractive target for drug development. The inhibition of C12orf60 function has been shown to result in the inhibition of PKA-mediated cellular processes, suggesting that targeting C12orf60 may be an effective way to treat various diseases. Further research is needed to fully understand the role of C12orf60 in disease progression and to develop effective diagnostic tests for its potential use.

Protein Name: Chromosome 12 Open Reading Frame 60

The "C12orf60 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about C12orf60 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets